Brentwood-based BioMimetic has filed yet another round of paperwork in hopes of gaining federal approval for its bone graft therapy, called Augment.
The company first submitted its only product to the Food and Drug Administration more than two years ago; earlier this year, while still waiting to be able to sell Augment in the US, nearly a quarter of the company’s staff were laid off. With the latest filing, BioMimetic officials say they’re hoping for an FDA verdict sometime next year.
On Air - 90.3 WPLN-FM